Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies. 

The pivotal Harmoni-GI3 study has started enrolling patients.

The company will imminently start its third pivotal trial of PF-08634404.

Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.

Global data are in the same ballpark as Chinese results presented earlier this year.

It’s a new term for biotech and its investors.

China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.

LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.